The Role and Antagonistic Effects of MiR-16-5p in the Regulation of ADP-Ribosylation Factor-Like Tumor Suppressor Gene 1 in Lung Cancer Cells

Overview

Journal Eurasian J Med

Publisher Aves

Specialty General Medicine

Date 2023 Nov 1

PMID 37909191

Authors

Tugba Nurcan Yuksel

Esra Bozgeyik

Ibrahim Bozgeyik

Affiliations

Soon will be listed here.

Abstract

Objective: ADP-ribosylation factor-like tumor suppressor gene 1 is a member of the Ras superfamily of small guanosine triphosphatases that are known to be involved in multiple regulatory pathways in the multistage development of human cancers. Also, ADP-ribosylation factor-like tumor suppressor gene 1 expression levels have been reported to be dramatically lower in both cancer cell lines and tumor tissues compared to controls. Accordingly, defects in the regulation of the ADP-ribosylation factor-like tumor suppressor gene 1 gene seems have key tumor suppressive effects in the formation and development of human cancers including lung cancer. Moreover, microRNAs regulating the expression of ADP-ribosylation factor-like tumor suppressor gene 1 have not been described previously. Accordingly, the present study aimed to reveal the influence of miR-16-5p on the regulation of ADP-ribosylation factor-like tumor suppressor gene 1 gene.

Materials And Methods: A549 lung adenocarcinoma cells were used. For the overexpression and silencing experiments of miR-16-5p synthetic microRNA mimics and inhibitors were used, respectively. Gene expression analyses were achieved with the help of quantitative real-time polymerase chain reaction.

Results: MiR-16-5p was identified to be predictive target of ADP-ribosylation factor-like tumor suppressor gene 1 and directly targets the expression of ADP-ribosylation factor-like tumor suppressor gene 1 as revealed by the overexpression and silencing experiments. Specifically, it was found that miR-16-5p-overexpressed A549 cells showed a decrease in ADP-ribosylation factor-like tumor suppressor gene 1 gene expression, whereas miR16-5p-suppressed cells showed an increase in expression. These findings possibly suggest that miR-16-5p is the direct regulatory microRNA that posttranscriptionally regulates the expression of ADP-ribosylation factor-like tumor suppressor gene 1.

Conclusion: Collectively, miR-16-5p seems to be a key regulatory molecule involved in the posttranscriptional regulation of the ADP-ribosylation factor-like tumor suppressor gene 1, and it might be responsible for the downregulation of this gene in lung cancer.

References

Peng Q, Chen Y, Li C . Long noncoding RNA Linc00210 promotes non-small cell lung cancer progression via sponging miR-16-5p/PTK2 axis. Eur Rev Med Pharmacol Sci. 2020; 24(18):9438-9452. DOI: 10.26355/eurrev_202009_23029. View

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

Abba M, Patil N, Leupold J, Moniuszko M, Utikal J, Niklinski J . MicroRNAs as novel targets and tools in cancer therapy. Cancer Lett. 2016; 387:84-94. DOI: 10.1016/j.canlet.2016.03.043. View

Akisik E, Yazici H, Dalay N . ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol Biol Rep. 2010; 38(1):343-8. DOI: 10.1007/s11033-010-0113-3. View

Yang X, Yu H, Xi M, Yang K, Pan X, Hu M . Association of the ARLTS1 variants with familial ovarian cancer risk in China. Int J Gynecol Cancer. 2009; 19(4):585-90. DOI: 10.1111/IGC.0b013e3181a39d03. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Gu Y, Wang X, Lu J, Lei Y, Zou J, Luo H . Effect of mir-16 on proliferation and apoptosis in human A549 lung adenocarcinoma cells. Int J Clin Exp Med. 2015; 8(3):3227-33. PMC: 4443046. View

Sellick G, Catovsky D, Houlston R . Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia. Leuk Res. 2006; 30(12):1573-6. DOI: 10.1016/j.leukres.2006.02.021. View

Li X, Gast A, Rudnai P, Gurzau E, Koppova K, Hemminki K . ARLTS1 polymorphisms and basal cell carcinoma of the skin. Hered Cancer Clin Pract. 2009; 5(1):25-9. PMC: 2736660. DOI: 10.1186/1897-4287-5-1-25. View

10.

Castellvi-Bel S, Castells A, de Cid R, Munoz J, Balaguer F, Gonzalo V . Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. Carcinogenesis. 2007; 28(8):1687-91. DOI: 10.1093/carcin/bgm098. View

11.

Frank B, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B . ARLTS1 variants and risk of colorectal cancer. Cancer Lett. 2006; 244(2):172-5. DOI: 10.1016/j.canlet.2005.12.006. View

12.

Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J . miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008; 36(16):5391-404. PMC: 2532718. DOI: 10.1093/nar/gkn522. View

13.

Yendamuri S, Trapasso F, Ferracin M, Cesari R, Sevignani C, Shimizu M . Tumor suppressor functions of ARLTS1 in lung cancers. Cancer Res. 2007; 67(16):7738-45. DOI: 10.1158/0008-5472.CAN-07-1481. View

14.

Frank B, Meyer P, Boettger M, Hemminki K, Stapelmann H, Gast A . ARLTS1 variants and melanoma risk. Int J Cancer. 2006; 119(7):1736-7. DOI: 10.1002/ijc.22008. View

15.

Siltanen S, Fischer D, Rantapero T, Laitinen V, Mpindi J, Kallioniemi O . ARLTS1 and prostate cancer risk--analysis of expression and regulation. PLoS One. 2013; 8(8):e72040. PMC: 3734304. DOI: 10.1371/journal.pone.0072040. View

16.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

17.

Fan L, Qi H, Teng J, Su B, Chen H, Wang C . Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer. Tumour Biol. 2015; 37(6):7777-84. DOI: 10.1007/s13277-015-4608-3. View

18.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

19.

Ke Y, Zhao W, Xiong J, Cao R . Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 2013; 587(18):3153-7. DOI: 10.1016/j.febslet.2013.08.010. View

20.

Siltanen S, Syrjakoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J . ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer. Eur J Hum Genet. 2008; 16(8):983-91. PMC: 3404127. DOI: 10.1038/ejhg.2008.43. View